Sermorelin – A Better Approach to Managing Age-Related Growth Hormone Deficiency

Source: Walker R.F., Clinical Interventions in Aging, 2007, PMC2699646

Purpose of the Article

To discuss the potential of Sermorelin as a more physiological and safer alternative to recombinant human growth hormone (rhGH) in adults with GH deficiency or age-related decline in its secretion.

Background

Traditional rhGH therapy is effective in counteracting somatic aging but carries several risks:

• Improper dosing can cause serious side effects.
• Exogenous GH creates non-physiological "square-wave" peaks that are not regulated by feedback.
• Legal frameworks restrict rhGH use to specific clinical indications (AIDS or confirmed GHD).

Sermorelin (GHRH 1–29 NH₂-acetate) is an analog of the natural hormone that stimulates GH secretion (GHRH), levels of which decline with age. By binding to pituitary receptors, it activates endogenous GH release, mimicking physiological pulsatility.

Key Advantages over rhGH

• Physiological control: Effects are regulated by somatostatin, preventing overdose.
• Pulsatile secretion: GH release is episodic rather than a constant peak, as with rhGH.
• No tachyphylaxis: Secretion remains responsive to stimuli due to the natural release rhythm.
• Supports pituitary function: Stimulates GH mRNA transcription and increases hormonal reserve.
• Slows aging of the endocrine axis: Helps preserve normal physiology with age.

Legal and Clinical Status

Unlike rhGH, Sermorelin has no federal restrictions for prescribing in adults, allowing clinicians to use it off-label within research protocols to evaluate its efficacy and safety.

Conclusion

• Sermorelin offers a more physiological approach to GHRT in adults.
• It reduces the risk of side effects and maintains natural regulation of the GH/IGF-1 axis.
• It can be used as a safe and legal alternative to maintain hormonal balance during aging.